Product Description
STRO-002, a folate receptor alpha (FolR_)-targeting ADC, is currently being investigated in a Phase 1 clinical trial for patients with ovarian and endometrial cancers and was granted Fast Track designation by the FDA for ovarian cancer. (Sourced from: https://www.sutrobio.com/sutro-biopharma-announces-interim-data-from-dose-expansion-cohort-of-stro-002-phase-1-study-for-patients-with-advanced-ovarian-cancer/)
Mechanisms of Action: FRa Antagonist
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: Fast Track - Ovarian Cancer *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sutro Biopharma, Inc.
Company Location: SOUTH SAN FRANCISCO CA 94080
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Austria, Belgium, China, Czech Republic, Denmark, Finland, France, Germany, Hungary, Ireland, Italy, Netherlands, Spain, United States
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Sutro Biopharma, Inc. presented P2 Ovarian Cancer results on 2024-12-10 for Luveltamab tazevibulin
- Clinical Outcomes Reported - Sutro Biopharma, Inc. announced they will present P2 Non-Small-Cell Lung Cancer results in 1H25 for Luveltamab tazevibulin
- Clinical Outcomes Reported - Sutro Biopharma, Inc. presented P1 Ovarian Cancer results on 2024-09-14 for Luveltamab tazevibulin
Highest Development Phases
Phase 2: Acute Myeloid Leukemia|Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cancer
Phase 1: Adenocarcinoma|Endometrial Cancer|Endometrioid Carcinoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03748186 |
STRO-002-GM1 | P1 |
Completed |
Ovarian Cancer|Adenocarcinoma|Endometrioid Carcinoma|Endometrial Cancer|Fallopian Tube Cancer|Peritoneal Cancer |
2024-06-04 |
21% |
2024-08-02 |
|
NCT06238687 |
TSL-B2276-1-01 | P2 |
Recruiting |
Ovarian Cancer |
2026-12-30 |
70% |
2024-02-03 |
Primary Endpoints|Treatments |
2023-506240-16-00 |
REFRaME-P1 | P2 |
Completed |
Acute Myeloid Leukemia |
2025-04-04 |
12% |
2025-05-02 |
Treatments |
2024-512477-27-00 |
STRO-002-GM3 | P2 |
Completed |
Peritoneal Cancer|Fallopian Tube Cancer|Ovarian Cancer |
2025-03-28 |
2025-05-02 |
Treatments |